Citi analyst Ashwin Shirvaikar lowered the firm’s price target on Genpact to $39 from $42 and keeps a Neutral rating on the shares. The company missed Q2 expectations and also lowered its outlook, the analyst tells investors in a research note. The firm’s estimates remain below Genpact’s reduced outlook.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on G: